A multi-institution team of lung cancer experts have received a new SU2C grant to bring technology-enabled immunotherapy monitoring to under-represented patients.
At ASCO 2022, Dr. Catherine Shu shared updated results from a trial of a combination therapy for patients with EGFR mutated non-small cell lung cancer.
The comprehensive lung cancer screening program brings together physicians and nurse practitioners from multiple disciplines to provide care for smokers and ex-smokers at high risk for lung cancer.
Columbia University researchers uncovered a signaling pathway in EGFR-mutant lung cancer responsible for driving recurrence and metastases, spreading to the brain.
A physician-researcher in thoracic oncology, Dr. Catherine Shu has a focused interest in improving outcomes for lung cancer patients with resectable disease.